Author:
Socha J.,Michalski W.,Gerard J.P.,Bujko K.
Reference5 articles.
1. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial;Conroy;Ann Oncol,2024
2. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial;Conroy;J Clin Oncol,2023
3. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial;Conroy;Lancet Oncol,2021
4. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set;de Gramont;J Clin Oncol,2010
5. Does total neoadjuvant treatment improve overall survival in rectal cancer? No, it does not;Socha;Ann Surg Oncol,2021